Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Merrell

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|September 14, 2022
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung CancerNathan Y Yu, Todd A DeWees, Molly M Voss, et al.
Frontiers in Oncology|May 28, 2021
Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9Roman O Kowalchuk, Scott C Lester, Rondell P Graham, et al.
Practical Radiation Oncology|February 13, 2022
Development and Internal Validation of a Recursive Partitioning Analysis-Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation TherapyRoman O Kowalchuk, Trey C Mullikin, William S Harmsen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 28, 2024
Assessment of minimum target dose as a predictor of local failure after spine SBRTRoman O Kowalchuk, Trey C Mullikin, Grant M Spears, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaAmro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapyHunter C Gits, Amy H Tang, William S Harmsen, et al.
Advances in Radiation Oncology|October 3, 2022
Single and Multifraction Spine Stereotactic Body Radiation Therapy and the Risk of Radiation Induced MyelopathyJ John Lucido, Trey C Mullikin, Feven Abraha, et al.
The Lancet. Oncology|September 11, 2023
Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trialRobert W Mutter, Sharmila Giri, Briant F Fruth, et al.
JAMA Oncology|January 27, 2022
Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal MetastasesRoman O Kowalchuk, Benjamin A Johnson-Tesch, Joseph T Marion, et al.
Journal of Neurosurgery. Spine|June 20, 2025
Sacral fracture risk after stereotactic spinal radiosurgery: a multi-institution, retrospective analysisEric A Goethe, Romulo A Andrade de Almeida, Francisco Call-Orellana, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|September 14, 2022
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung CancerNathan Y Yu, Todd A DeWees, Molly M Voss, et al.
Frontiers in Oncology|May 28, 2021
Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9Roman O Kowalchuk, Scott C Lester, Rondell P Graham, et al.
Practical Radiation Oncology|February 13, 2022
Development and Internal Validation of a Recursive Partitioning Analysis-Based Model Predictive of Pain Flare Incidence After Spine Stereotactic Body Radiation TherapyRoman O Kowalchuk, Trey C Mullikin, William S Harmsen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 28, 2024
Assessment of minimum target dose as a predictor of local failure after spine SBRTRoman O Kowalchuk, Trey C Mullikin, Grant M Spears, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaAmro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapyHunter C Gits, Amy H Tang, William S Harmsen, et al.
Advances in Radiation Oncology|October 3, 2022
Single and Multifraction Spine Stereotactic Body Radiation Therapy and the Risk of Radiation Induced MyelopathyJ John Lucido, Trey C Mullikin, Feven Abraha, et al.
The Lancet. Oncology|September 11, 2023
Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trialRobert W Mutter, Sharmila Giri, Briant F Fruth, et al.
JAMA Oncology|January 27, 2022
Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal MetastasesRoman O Kowalchuk, Benjamin A Johnson-Tesch, Joseph T Marion, et al.
Journal of Neurosurgery. Spine|June 20, 2025
Sacral fracture risk after stereotactic spinal radiosurgery: a multi-institution, retrospective analysisEric A Goethe, Romulo A Andrade de Almeida, Francisco Call-Orellana, et al.
Pageof 9